Adam Offenhartz > Gibson, Dunn & Crutcher LLP > New York, United States > Lawyer Profile

Gibson, Dunn & Crutcher LLP
200 PARK AVENUE
NEW YORK, NY 10166-0193
NEW YORK
United States

Work Department

Adam focuses on mergers and acquisition battles, related shareholder class and derivative actions, broken deal fights, board battles and appraisal and earn-out disputes.  He regularly advises investors, directors of public and private companies, special board committees and stockholders on various litigation related topics.

Adam also has an active domestic and international arbitration practice with an emphasis on insurance and reinsurance disputes and cross-border issues.  He has also handled a number of regulatory, disciplinary and ad hoc proceedings.  Adam regularly represents plaintiffs/claimants for whom he has recovered substantial sums or achieved significant injunctive relief.

Career

For more information, please visit https://www.gibsondunn.com/lawyer/offenhartz-adam-h/.

Lawyer Rankings

United States > Dispute resolution > M&A litigation: defense

Gibson, Dunn & Crutcher LLP‘s securities litigation practice frequently handles M&A-related cases, notably in finance, technology, healthcare, energy, accounting and insurance sectors. It is particularly well-respected for its takeover defense work, having handled numerous hostile takeover matters in the US and internationally. Monica Loseman in Denver, Brian Lutz in San Francisco and Craig Varnen in Los Angeles lead the securities litigation practice, in which New York-based Adam Offenhartz is a specialist in M&A litigation, including class action and derivative actions, appraisal cases and earnout disputes. Lutz recently won the dismissal of a class action for Elliott Management arising from the company’s acquisition of Gigamon. Among his recent highlights, Offenhartz acted for Afred E. Mann Trust, a controlling stockholder in medical device company Bioness, in a challenge to its acquisition of Bioventus, which closed successfully after the court denied a dissident directors’ final application for immediate injunctive relief.